Second Nature is the only provider in this comparison with peer-reviewed, published clinical outcomes specific to their programme
The funding sources had no role in the design of this study nor any role during its execution, analyses, data interpretation, or decision to submit results
One video visit every three months is required, additional video visits cost nothing extra, and portal messaging is open between appointments
Dubbed the Barbie drug, Melanotan-II promises users a rapid tan without long hours in the sun
Methodology and Sources This analysis is based on publicly available sources as of December 26, 2025: FDA communications: Compounding safety alerts, prescribing information, and regulatory guidance Novo Nordisk announcements: Wegovy pill approval, OASIS 4 trial results, pricing disclosures Independent reporting and primary sources: ABC News coverage and Novo Nordisks announcement on December 22, 2025 FDA oral Wegovy approval MEDVi terms and disclosures: Platform structure, pricing, and regulatory disclaimers Key Sources Cited: ABC News: "FDA approves Wegovy pill for weight loss" (December 22, 2025) Novo Nordisk: Official press release on FDA approval and OASIS 4 trial data (December 22, 2025) FDA Safety Communications: 20242025 alerts on compounded semaglutide dosing errors All regulatory references are based on FDA publications and third-party reporting available at the time of publication
